In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .
Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under lovastatin treatment: a double-blind randomized controlled clinical trial.
BACKGROUND AND AIMS Hypercholesterolemia is one of the predisposing factors of cardiovascular diseases . A positive correlation of homocysteine ( Hcy ) concentration with total cholesterol is described . Lovastatin , one of the most administered agents in hypercholesterolemia , is not effective in lowering the level of serum Hcy and increasing serum total antioxidant capacity ( TAC ) . This study was performed to evaluate the effects of folate supplementation on lowering Hcy level and changes of TAC in asymptomatic hypercholesterolemic adults under lovastatin treatment . METHODS This was a double-blind r and omized controlled clinical trial . Forty asymptomatic newly diagnosed hypercholesterolemic individuals were recruited . Patients were r and omized into two groups : group A--20 patients supplemented for 8 weeks with folate ( 5 mg daily ) and group B--20 patients receiving placebo . Lovastatin was administered to both groups . Laboratory lipid profiles , serum Hcy and folate concentration , and TAC were measured at the beginning and after the 8(th ) week of the study period . RESULTS After folate supplementation in group A subjects , serum Hcy was significantly decreased ( 13.35+/-5.01 micromol/L to 8.43+/-2.52 micromol/L , p=0.001 ) , whereas no significant changes occurred in group B ( p>0.05 ) . A significant increase in TAC was only observed in group A ( 1.54+/-0.24 micromol/L to 1.96+/-0.42 micromol/L , p<0.001 ) . CONCLUSIONS Folate supplementation decreases the serum level of Hcy and increases TAC . It seems that a pharmacological dose of folate supplementation could potentially decrease the risk of cardiovascular diseases by reducing serum level of Hcy in adults with hypercholesterolemia
In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .